|

ORIC-114 Dose 1 + amivantamab Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • ORIC Pharmaceuticals1

Indications

  • EGFR-mutated NSCLC1
  • EGFR Exon 20 Insertion Mutations1
  • Solid Tumors1
  • NSCLC1
  • Cancer1

New York, New York1 trial

ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC

NYU Langone Health

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.